The estimated Net Worth of Hans Moebius is at least $465 millier dollars as of 2 June 2023. Dr Moebius owns over 7,882 units of Athira Pharma stock worth over $39,926 and over the last 4 years he sold ATHA stock worth over $0. In addition, he makes $425,058 as Chief Medical Officer at Athira Pharma.
Dr has made over 5 trades of the Athira Pharma stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 7,882 units of ATHA stock worth $10,641 on 2 June 2023.
The largest trade he's ever made was exercising 28,372 units of Athira Pharma stock on 21 July 2021 worth over $38,302. On average, Dr trades about 5,914 units every 68 days since 2021. As of 2 June 2023 he still owns at least 81,482 units of Athira Pharma stock.
You can see the complete history of Dr Moebius stock trades at the bottom of the page.
Dr. Hans Moebius is the Chief Medical Officer at Athira Pharma.
As the Chief Medical Officer of Athira Pharma, the total compensation of Dr Moebius at Athira Pharma is $425,058. There are no executives at Athira Pharma getting paid more.
Dr Moebius is 64, he's been the Chief Medical Officer of Athira Pharma since . There are no older and 3 younger executives at Athira Pharma.
Hans's mailing address filed with the SEC is C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011.
Over the last 4 years, insiders at Athira Pharma have traded over $100,296 worth of Athira Pharma stock and bought 5,411,219 units worth $62,123,025 . The most active insiders traders include Advisors Llcperceptive Life..., Investments, Lpwong Roderic... et Joseph Edelman. On average, Athira Pharma executives and independent directors trade stock every 33 days with the average trade being worth of $62,547. The most recent stock trade was executed by Andrew Gengos on 3 September 2024, trading 1,272 units of ATHA stock currently worth $725.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Athira Pharma executives and other stock owners filed with the SEC include: